MALT lymphoma · 5 regimens
Cost vs Efficacy · 2 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Cladribine and Rituximab Variant #01 | — | R 48 077 | 21d | — | — | ~6 | ~R 288 462 indirect | — |
Clarithromycin monotherapy Variant #01 | — | R 10 317 | 21d | — | — | ~4 | ~R 41 268 indirect | — |
Bortezomib monotherapy Variant #03 | — | R 6 762 | 21d | ~30.3 mo | — | ~8 | ~R 54 096 PFS proxy · indirect | 5 |
Lenalidomide monotherapy Variant #01 | — | R 2 178 | 28d | ~30.8 mo | — | ~24 | ~R 52 272 PFS proxy · indirect | 2 |
Rituximab monotherapy Variant #09 Partial | — | — | 28d | ~20.3 mo | — | ~1 | — | 17 |
5 of 5 regimens shown